Initial outcomes and insights from a novel high‐risk prostate cancer screening clinic

This study aimed to characterize the clinical features of this cohort. Thirty‐five individuals with increased PCa risk were followed by the PCRC with a median age of 47 years of age. Individuals with prostates and BRCA1/2 PVs, among other germline PVs, can benefit from a comprehensive interdisciplinary approach to high‐risk management. PCa was identified in an individual with a non‐BRCA PV, emphasizing the importance and need for high‐risk screening guidelines across all genes with increased risk for PCa. “Outlier” patient response scores demonstrate that some participants experienced worse symptoms or anxiety than was indicated by median scores alone.